NCT06206850View on ClinicalTrials.gov

Neo-Bio-ADAURA: a Phase II Study to Evaluate Mechanisms of Resistance to Neoadjuvant Osimertinib

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 19, 2024

Primary Completion Date

January 31, 2029

Study Completion Date

January 1, 2030

Conditions
Non-squamous NSCLC
Interventions
DRUG

Osimertinib

Oral Osimertinib 80 mg once daily (QD) for the duration of 9 weeks (3 cycles).

Trial Locations (2)

522651

RECRUITING

Sheba Medical Center, Ramat Gan

5590000

RECRUITING

Sheba Medical Center, Jusidman Cancer Center, Ramat Gan

All Listed Sponsors
lead

Jair Bar, M.D., Ph.D.

OTHER_GOV